{"transactions":[{"id":728729,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:52:08.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":3127,"derivative":{"exercise_price":162.99,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":3127},"source":{"system":"sec-edgar","filing":"0001610717-26-000289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071726000289/form4.xml","form_type":"4"}},{"id":728728,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-23T21:52:08.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":1191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,191 restricted stock units."}],"balance_after":2340075,"source":{"system":"sec-edgar","filing":"0001610717-26-000289","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071726000289/form4.xml","form_type":"4"}},{"id":737785,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2026-06-15T21:17:59.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":162221,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series F Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series F Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series F Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series F Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":105414},"source":{"system":"sec-edgar","filing":"0001193125-26-271300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271300/ownership.xml","form_type":"4"}},{"id":737784,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:17:59.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":105414,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series F Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the \"IPO\"). The Preferred Stock had no expiration date."}],"balance_after":105414,"source":{"system":"sec-edgar","filing":"0001193125-26-271300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526271300/ownership.xml","form_type":"4"}},{"id":741691,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:53:23.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":20215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":20215,"derivative":{"exercise_price":20,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":20215},"source":{"system":"sec-edgar","filing":"0001193125-26-267806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526267806/ownership.xml","form_type":"4"}},{"id":743258,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:30:06.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":32947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":32947,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":32947},"source":{"system":"sec-edgar","filing":"0001193125-26-265906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526265906/ownership.xml","form_type":"4"}},{"id":1083969,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":106.14,"underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083968,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":63.66,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083967,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":50.64,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083966,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":87.13,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083965,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":76.24,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083964,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.77,"underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083963,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":69.79,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083962,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":74160,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1083961,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T23:46:35.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3902,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration."}],"balance_after":74160,"source":{"system":"sec-edgar","filing":"0001104659-25-069385","document":"tm2521348-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000110465925069385/tm2521348-3_4seq1.xml","form_type":"4"}},{"id":1099102,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-30T20:25:14.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":11574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":11574,"derivative":{"exercise_price":37.48,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":11574},"source":{"system":"sec-edgar","filing":"0001610717-25-000270","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071725000270/form4.xml","form_type":"4"}},{"id":1099101,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-30T20:25:14.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":3142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,142 Restricted Stock Units."}],"balance_after":2338884,"source":{"system":"sec-edgar","filing":"0001610717-25-000270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071725000270/form4.xml","form_type":"4"}},{"id":1102493,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T20:23:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":3902,"price":128.12,"value":499924.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":78062,"source":{"system":"sec-edgar","filing":"0001415889-25-018075","document":"form4-06242025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588925018075/form4-06242025_080609.xml","form_type":"4"}},{"id":1118081,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:45:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083903/ownership.xml","form_type":"4"}},{"id":1118080,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:45:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0000950170-25-083903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083903/ownership.xml","form_type":"4"}},{"id":1119830,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:52:37.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":136681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":136681,"derivative":{"exercise_price":3.36,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":136681},"source":{"system":"sec-edgar","filing":"0000950170-25-083312","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025083312/ownership.xml","form_type":"4"}},{"id":1467064,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T21:06:44.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":15955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date."}],"balance_after":15955,"derivative":{"exercise_price":37.54,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":15955},"source":{"system":"sec-edgar","filing":"0001610717-24-000375","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071724000375/form4.xml","form_type":"4/A","original_submission_date":"2024-06-24"}},{"id":1467063,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-28T21:06:44.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,248 restricted stock units (\"RSUs\")."}],"balance_after":2335742,"source":{"system":"sec-edgar","filing":"0001610717-24-000375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071724000375/form4.xml","form_type":"4/A","original_submission_date":"2024-06-24"}},{"id":1470473,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T20:21:57.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":16700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":16700,"derivative":{"exercise_price":37.54,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":16700},"source":{"system":"sec-edgar","filing":"0001610717-24-000360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071724000360/form4.xml","form_type":"4"}},{"id":1470472,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-24T20:21:57.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,800 Restricted Stock Units."}],"balance_after":2336294,"source":{"system":"sec-edgar","filing":"0001610717-24-000360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071724000360/form4.xml","form_type":"4"}},{"id":1478692,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T21:32:54.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016980","document":"form4-06142024_090651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588924016980/form4-06142024_090651.xml","form_type":"4"}},{"id":1478691,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T21:32:54.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":74160,"source":{"system":"sec-edgar","filing":"0001415889-24-016980","document":"form4-06142024_090651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588924016980/form4-06142024_090651.xml","form_type":"4"}},{"id":1487032,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T21:11:16.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":7.41,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-24-070851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024070851/ownership.xml","form_type":"4"}},{"id":1487031,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T21:11:16.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0000950170-24-070851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024070851/ownership.xml","form_type":"4"}},{"id":1490171,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T00:03:29.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":102225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":102225,"derivative":{"exercise_price":6.79,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":102225},"source":{"system":"sec-edgar","filing":"0000950170-24-069555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024069555/ownership.xml","form_type":"4"}},{"id":1742055,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Earn-out Shares","published_at":"2023-11-15T01:14:13.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":296039,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares.  The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares.  The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares.  The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the \"Earn-out Shares\"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares.  The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares."}],"balance_after":296039,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":296039},"source":{"system":"sec-edgar","filing":"0001610717-23-000355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071723000355/form4.xml","form_type":"4"}},{"id":1742054,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T01:14:13.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":2091672,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the \"Effective Time\"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the \"Company\"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the \"Effective Time\"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the \"Company\"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,200 restricted stock units."}],"balance_after":2331494,"source":{"system":"sec-edgar","filing":"0001610717-23-000355","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071723000355/form4.xml","form_type":"4"}},{"id":1745798,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Earn-out Shares","published_at":"2023-11-09T16:05:13.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2892491,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the \"DeSPAC Merger Agreement\"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the \"Earn-out Shares\"), (i) 2,024,743 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the \"DeSPAC Merger Agreement\"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the \"Earn-out Shares\"), (i) 2,024,743 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the \"Exchange Ratio\") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement."}],"balance_after":0,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2892491},"source":{"system":"sec-edgar","filing":"0000899243-23-020290","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020290/doc4.xml","form_type":"4"}},{"id":1745797,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T16:05:13.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2194499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an \"In-the-Money Option\") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration)."}],"balance_after":0,"derivative":{"exercise_price":2.68,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":2194499},"source":{"system":"sec-edgar","filing":"0000899243-23-020290","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020290/doc4.xml","form_type":"4"}},{"id":1745796,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-11-09T16:05:13.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18810000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the \"Exchange Ratio\") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-020290","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020290/doc4.xml","form_type":"4"}},{"id":1844994,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T23:03:29.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":63.66,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-23-010258","document":"form4-06232023_110625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588923010258/form4-06232023_110625.xml","form_type":"4"}},{"id":1844993,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T23:03:29.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":71918,"source":{"system":"sec-edgar","filing":"0001415889-23-010258","document":"form4-06232023_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588923010258/form4-06232023_110625.xml","form_type":"4"}},{"id":1845707,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T20:12:48.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":1.61,"exercise_date":"2024-06-22","expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-039337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919123039337/doc4.xml","form_type":"4"}},{"id":1858498,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:16:41.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"New Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":18400,"derivative":{"exercise_price":24.84,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18400},"source":{"system":"sec-edgar","filing":"0001610717-23-000135","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071723000135/form4.xml","form_type":"4"}},{"id":1858497,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-12T20:16:41.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On August 17, 2022, December 7, 2022, and January 27, 2023, Third Rock Ventures GP III, L.P. distributed 17,220, 103,090 and 59,394 shares, respectively, to the Reporting Person through in-kind, pro rata distributions without value. The distributions were exempt Section 16 of the Exchange Act pursuant to Rule 16a-9."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,200 restricted stock units."}],"balance_after":239822,"source":{"system":"sec-edgar","filing":"0001610717-23-000135","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000161071723000135/form4.xml","form_type":"4"}},{"id":1862578,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T01:36:06.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service  with the Issuer as of each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.55,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-23-015016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000089924323015016/doc4.xml","form_type":"4"}},{"id":1862577,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:36:06.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-23-015016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000089924323015016/doc4.xml","form_type":"4"}},{"id":1872168,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T22:27:42.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":66055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":66055,"derivative":{"exercise_price":11.14,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":66055},"source":{"system":"sec-edgar","filing":"0001209191-23-033428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919123033428/doc4.xml","form_type":"4"}},{"id":2068409,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Earn-out Shares","published_at":"2023-01-04T21:57:03.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":15148,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 10,604 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will\nbe forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 10,604 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will\nbe forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 10,604 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will\nbe forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 10,604 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will\nbe forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."}],"balance_after":2892491,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":15148},"source":{"system":"sec-edgar","filing":"0001104659-23-001119","document":"tm231679-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923001119/tm231679-1_4seq1.xml","form_type":"4"}},{"id":2207229,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-15T21:24:09.000Z","date":"2022-07-14","kind":"grant","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":2.69,"exercise_date":"2023-07-14","expiration_date":"2032-07-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-042274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919122042274/doc4.xml","form_type":"4"}},{"id":2218564,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T01:54:18.000Z","date":"2022-06-21","kind":"grant","acquired":true,"price":0,"reported_value":5300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":50.64,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-22-007130","document":"form4-06302022_060607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588922007130/form4-06302022_060607.xml","form_type":"4"}},{"id":2218563,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T01:54:18.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":69318,"source":{"system":"sec-edgar","filing":"0001415889-22-007130","document":"form4-06302022_060607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000141588922007130/form4-06302022_060607.xml","form_type":"4"}},{"id":2220318,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T20:31:14.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.9,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-22-024404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000089924322024404/doc4.xml","form_type":"4"}},{"id":2227171,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:03:02.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":18400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 16, 2022 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":18400,"derivative":{"exercise_price":16.8,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":18400},"source":{"system":"sec-edgar","filing":"0001567619-22-013106","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761922013106/doc1.xml","form_type":"4"}},{"id":2227170,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T21:03:02.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,200 Restricted Stock Units."}],"balance_after":54918,"source":{"system":"sec-edgar","filing":"0001567619-22-013106","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761922013106/doc1.xml","form_type":"4"}},{"id":2253660,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:37:05.000Z","date":"2022-05-27","kind":"grant","acquired":true,"shares":41597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":41597,"derivative":{"exercise_price":17.33,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":41597},"source":{"system":"sec-edgar","filing":"0001209191-22-032676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919122032676/doc4.xml","form_type":"4"}},{"id":2272547,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T22:19:22.000Z","date":"2022-05-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.44,"exercise_date":"2023-05-09","expiration_date":"2032-05-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-028956","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919122028956/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-11"}},{"id":2272546,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T22:19:22.000Z","date":"2022-05-09","kind":"grant","acquired":true,"shares":312612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 9, 2022, the Issuer awarded the Reporting Person restricted stock in the amount indicated in connection with the merger between the Issuer and ModeX Therapeutics, Inc. (\"ModeX\"), pursuant to which ModeX became a subsidiary of the Issuer."}],"balance_after":312612,"source":{"system":"sec-edgar","filing":"0001209191-22-028956","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919122028956/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-11"}},{"id":2275225,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-12T01:00:11.000Z","date":"2022-05-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.44,"exercise_date":"2023-05-09","expiration_date":"2032-05-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919122028424/doc4.xml","form_type":"4"}},{"id":2275224,"issuer":{"id":4891,"kind":"organization","name":"OPKO HEALTH, INC."},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T01:00:11.000Z","date":"2022-05-09","kind":"grant","acquired":true,"shares":312612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 9, 2022, the Issuer awarded the Reporting Person restricted stock  in the amount indicated. The restricted stock vests in four equal installments, beginning on May 9, 2023."}],"balance_after":312612,"source":{"system":"sec-edgar","filing":"0001209191-22-028424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/944809/000120919122028424/doc4.xml","form_type":"4"}},{"id":2462630,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Earn-out Shares","published_at":"2021-12-21T06:30:22.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":2877343,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 2,014,139 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 2,014,139 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 2,014,139 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 2,014,139 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."}],"balance_after":2877343,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":2877343},"source":{"system":"sec-edgar","filing":"0000899243-21-049124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049124/doc4.xml","form_type":"4"}},{"id":2462629,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-21T06:30:22.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":2194499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the \"2019 Plan\") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock.  The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing September 1, 2021, subject to the  Reporting Person's continuous service as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the \"2019 Plan\") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock.  The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing September 1, 2021, subject to the  Reporting Person's continuous service as of each vesting date."}],"balance_after":2194499,"derivative":{"exercise_price":2.68,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":2194499},"source":{"system":"sec-edgar","filing":"0000899243-21-049124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049124/doc4.xml","form_type":"4"}},{"id":2462628,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T06:30:22.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":18810000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."}],"balance_after":18810000,"source":{"system":"sec-edgar","filing":"0000899243-21-049124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049124/doc4.xml","form_type":"4"}},{"id":2560953,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:47:15.000Z","date":"2021-08-26","kind":"other","acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Third Rock Ventures GP IV, L.P., of which the reporting person is a limited partner."}],"balance_after":4100,"source":{"system":"sec-edgar","filing":"0000899243-21-037336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321037336/doc4.xml","form_type":"4"}},{"id":2655669,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-24T21:14:50.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":12659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":12659,"derivative":{"exercise_price":32.93,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":12659},"source":{"system":"sec-edgar","filing":"0001567619-21-012587","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761921012587/doc1.xml","form_type":"4"}},{"id":2655668,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T21:14:50.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":3617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,617 Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 10, 2020, December 3, 2020, and February 25, 2021, Third Rock Ventures GP III, L.P. distributed 639, 639 and 43,015 shares, respectively, to the Reporting Person through in-kind, pro rata distributions without value. The distributions were exempt Section 16 of the Exchange Act pursuant to Rule 16a-9."}],"balance_after":49718,"source":{"system":"sec-edgar","filing":"0001567619-21-012587","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761921012587/doc1.xml","form_type":"4"}},{"id":2680601,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:15:35.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006415","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911021006415/edgar.xml","form_type":"4"}},{"id":2680600,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T20:15:35.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":66718,"source":{"system":"sec-edgar","filing":"0001179110-21-006415","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911021006415/edgar.xml","form_type":"4"}},{"id":2683360,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T22:27:33.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":12.91,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-21-021836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321021836/doc4.xml","form_type":"4"}},{"id":2701072,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-21T23:43:16.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":16000,"derivative":{"exercise_price":30.09,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-21-035113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919121035113/doc4.xml","form_type":"4"}},{"id":2789379,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T11:42:45.000Z","date":"2021-03-11","kind":"other","acquired":true,"shares":28538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner."}],"balance_after":234175,"source":{"system":"sec-edgar","filing":"0001209191-21-021057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919121021057/doc4.xml","form_type":"4"}},{"id":2846525,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-20T01:00:24.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":30194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner."}],"balance_after":205637,"source":{"system":"sec-edgar","filing":"0001209191-21-012595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919121012595/doc4.xml","form_type":"4"}},{"id":2872320,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-10T01:00:18.000Z","date":"2021-02-05","kind":"other","acquired":true,"shares":70956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner."}],"balance_after":175443,"source":{"system":"sec-edgar","filing":"0001209191-21-009057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000120919121009057/doc4.xml","form_type":"4"}},{"id":3078930,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-21T23:14:47.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":371027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":104487},"source":{"system":"sec-edgar","filing":"0000899243-20-019839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000089924320019839/doc4.xml","form_type":"4"}},{"id":3078929,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T23:14:47.000Z","date":"2020-07-20","kind":"exercise","acquired":true,"shares":104487,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":104487,"source":{"system":"sec-edgar","filing":"0000899243-20-019839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000089924320019839/doc4.xml","form_type":"4"}},{"id":3098326,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T20:11:32.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007795","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911020007795/edgar.xml","form_type":"4"}},{"id":3098325,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T20:11:32.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":64468,"source":{"system":"sec-edgar","filing":"0001179110-20-007795","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911020007795/edgar.xml","form_type":"4"}},{"id":3101724,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T20:20:31.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007723","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911020007723/edgar.xml","form_type":"4"}},{"id":3101723,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T20:20:31.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":62218,"source":{"system":"sec-edgar","filing":"0001179110-20-007723","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911020007723/edgar.xml","form_type":"4"}},{"id":3104059,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T19:37:05.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":6329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 17, 2020 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date."}],"balance_after":6329,"derivative":{"exercise_price":36.57,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":6329},"source":{"system":"sec-edgar","filing":"0001567619-20-012447","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761920012447/doc1.xml","form_type":"4"}},{"id":3104058,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-19T19:37:05.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":1808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,808 Restricted Stock Units."}],"balance_after":1808,"source":{"system":"sec-edgar","filing":"0001567619-20-012447","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000156761920012447/doc1.xml","form_type":"4"}},{"id":3116472,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-09T20:32:28.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":9.99,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-20-015808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924320015808/doc4.xml","form_type":"4"}},{"id":3474472,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"exercise","acquired":false,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 21, 2017. This option vested with respect to 100% of the shares underlying the option on June 20, 2018."}],"balance_after":0,"derivative":{"exercise_price":46.02,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3474471,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"exercise","acquired":false,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on June 23, 2016. This option vested with respect to 100% of the shares underlying the option on June 20, 2017."}],"balance_after":0,"derivative":{"exercise_price":19.53,"expiration_date":"2026-06-23","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3474470,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"sale","acquired":false,"shares":968,"price":91.55,"value":88620.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.45 to $91.68 per share."}],"balance_after":60906,"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3474469,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"sale","acquired":false,"shares":20850,"price":92.03,"value":1918825.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.69 to $92.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4."}],"balance_after":61874,"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3474468,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"exercise","acquired":true,"shares":10909,"price":46.02,"value":502032.18,"ownership":{"direct":true},"balance_after":82724,"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3474467,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T23:23:38.000Z","date":"2019-06-27","kind":"exercise","acquired":true,"shares":10909,"price":19.53,"value":213052.77,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 7,657 shares received on April 4, 2019 through a distribution of shares in kind by Third Rock Ventures GP II, L.P. to its partners."}],"balance_after":71815,"source":{"system":"sec-edgar","filing":"0001179110-19-008262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019008262/edgar.xml","form_type":"4"}},{"id":3482264,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T20:35:16.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":1312,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-19-007980","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019007980/edgar.xml","form_type":"4"}},{"id":3482263,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T20:35:16.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":4875,"derivative":{"exercise_price":96.77,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001179110-19-007980","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911019007980/edgar.xml","form_type":"4"}},{"id":3494324,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-11T21:00:05.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":13.4,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-19-016407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924319016407/doc4.xml","form_type":"4"}},{"id":3854986,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"stock option (right to buy)","published_at":"2018-08-02T16:03:02.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":13385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F3","text":"The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":24.21,"exercise_date":"2015-06-18","expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":13385},"source":{"system":"sec-edgar","filing":"0001209191-18-044916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044916/doc4.xml","form_type":"4"}},{"id":3854985,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-02T16:03:02.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":73173,"price":137,"value":10024701.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-044916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044916/doc4.xml","form_type":"4"}},{"id":3882346,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-27T20:24:15.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"Prior to the conversion, the Fund held 20,102,478 shares of Series A Preferred Stock and 340,566 shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Prior to the conversion, the shares of Common Stock underlying the Series A Preferred Stock and Series B Preferred Stock held by the Fund were 7,779,656 and 131,799, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000899243-18-018315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018315/doc4.xml","form_type":"4"}},{"id":3882345,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-06-27T20:24:15.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"Prior to the conversion, the Fund held 20,102,478 shares of Series A Preferred Stock and 340,566 shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Prior to the conversion, the shares of Common Stock underlying the Series A Preferred Stock and Series B Preferred Stock held by the Fund were 7,779,656 and 131,799, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000899243-18-018315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018315/doc4.xml","form_type":"4"}},{"id":3882344,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T20:24:15.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 7,911,455 shares held by Third Rock Ventures IV, L.P. (the \"Fund\") received by the Fund upon conversion of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") upon closing of the Issuer's initial public offering on June 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-018315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018315/doc4.xml","form_type":"4"}},{"id":3883875,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T20:54:59.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019."}],"balance_after":29318,"derivative":{"exercise_price":69.79,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-008997","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911018008997/edgar.xml","form_type":"4"}},{"id":3934430,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T23:38:26.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On May 11, 2018, TRV II sold (i) 71,778 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.03 to $78.73, inclusive, at a weighted average price per share of $78.0398.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 11, 2018, TRV II sold (i) 71,778 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.03 to $78.73, inclusive, at a weighted average price per share of $78.0398.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"After the above transaction, TRV II owned 878,875 shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-012782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000089924318012782/doc4.xml","form_type":"4"}},{"id":3934429,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T23:38:26.000Z","date":"2018-05-10","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 210,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.05 to $80.25, inclusive, at a weighted average price per share of $80.0503 and (ii) 200 shares of Common Stock of the Issuer at a price of $81.11 per share.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 10, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 210,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.05 to $80.25, inclusive, at a weighted average price per share of $80.0503 and (ii) 200 shares of Common Stock of the Issuer at a price of $81.11 per share.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"After the above transaction, TRV II owned 950,653 shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-012782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000089924318012782/doc4.xml","form_type":"4"}},{"id":3936725,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-11T20:34:48.000Z","date":"2018-05-09","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 9, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 810,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.05 to $79.42, inclusive, at a weighted average price per share of $79.0502 and (ii) 15,400 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.07 to $80.12, inclusive, at a weighted average price per share of $80.0713.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 810,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.05 to $79.42, inclusive, at a weighted average price per share of $79.0502 and (ii) 15,400 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.07 to $80.12, inclusive, at a weighted average price per share of $80.0713.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"After the above transaction, TRV II owned 1,160,853 shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000089924318012543/doc4.xml","form_type":"4"}},{"id":3942298,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-08T20:57:19.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On May 7, 2018, TRV II sold (i) 284,378 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.10 to $79.07, inclusive, at a weighted average price per share of $78.5484 and (ii) 33,122 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.12 to $79.57, inclusive, at a weighted average price per share of $79.3597.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 7, 2018, TRV II sold (i) 284,378 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.10 to $79.07, inclusive, at a weighted average price per share of $78.5484 and (ii) 33,122 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.12 to $79.57, inclusive, at a weighted average price per share of $79.3597.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"After the above transaction, TRV II owned 1,986,253 shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-011871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000089924318011871/doc4.xml","form_type":"4"}},{"id":3942297,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-08T20:57:19.000Z","date":"2018-05-04","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 4, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 130,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.35 to $79.12, inclusive, at a weighted average price per share of $78.9148 and (ii) 20,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.40 to $79.80, inclusive, at a weighted average price per share of $79.4912.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 4, 2018, Third Rock Ventures II, L.P. (\"TRV II\") sold (i) 130,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.35 to $79.12, inclusive, at a weighted average price per share of $78.9148 and (ii) 20,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.40 to $79.80, inclusive, at a weighted average price per share of $79.4912.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"After the above transaction, TRV II owned 2,303,753 shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-011871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000089924318011871/doc4.xml","form_type":"4"}},{"id":4273316,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T20:26:21.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018."}],"balance_after":21818,"derivative":{"exercise_price":46.02,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-17-009523","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911017009523/edgar.xml","form_type":"4"}},{"id":4274570,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T16:04:48.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":5786,"price":40.05,"value":231729.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted by the Issuer pursuant to its 2013 Stock Option and Incentive Plan and the Issuer's Non-Employee Director Compensation Policy. The restricted stock units vest on the earlier of June 20, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board of Directors, or immediately upon the death or disability of the director or upon a change-of-control of the Issuer."}],"balance_after":73173,"source":{"system":"sec-edgar","filing":"0001209191-17-041329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117041329/doc4.xml","form_type":"4"}},{"id":4277148,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-19T20:04:18.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018."}],"balance_after":11538,"derivative":{"exercise_price":15.63,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-17-009253","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1319446/000117911017009253/edgar.xml","form_type":"4"}}],"next_cursor":"2017-06-19T20:04:18.000000Z,4277148"}